pCXLE-dCas9VP192-T2A-EGFP-shP53 Citations (3)
Originally described in: Conditionally Stabilized dCas9 Activator for Controlling Gene Expression in Human Cell Reprogramming and Differentiation.Balboa D, Weltner J, Eurola S, Trokovic R, Wartiovaara K, Otonkoski T Stem Cell Reports. 2015 Sep 8;5(3):448-59. doi: 10.1016/j.stemcr.2015.08.001. PubMed Journal
Articles Citing pCXLE-dCas9VP192-T2A-EGFP-shP53
| Articles |
|---|
Human pluripotent reprogramming with CRISPR activators.
Weltner J, Balboa D, Katayama S, Bespalov M, Krjutskov K, Jouhilahti EM, Trokovic R, Kere J, Otonkoski T.
Nat Commun. 2018 Jul 6;9(1):2643. doi: 10.1038/s41467-018-05067-x.
PubMed
Associated Plasmids |
| Reprogramming of Fibroblasts to Human iPSCs by CRISPR Activators. Weltner J, Trokovic R. Methods Mol Biol. 2021;2239:175-198. doi: 10.1007/978-1-0716-1084-8_12. PubMed |
CRISPR activation enables high-fidelity reprogramming into human pluripotent stem cells.
Sokka J, Yoshihara M, Kvist J, Laiho L, Warren A, Stadelmann C, Jouhilahti EM, Kilpinen H, Balboa D, Katayama S, Kyttala A, Kere J, Otonkoski T, Weltner J, Trokovic R.
Stem Cell Reports. 2022 Feb 8;17(2):413-426. doi: 10.1016/j.stemcr.2021.12.017. Epub 2022 Jan 20.
PubMed
Associated Plasmids |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.